Clinical Trial

A Study of KC1036 in Patients with Advanced Solid Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated October 17, 2024 (before its estimated October 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this study is to evaluate the safety，tolerability, pharmacokinetics, and preliminary efficacy of KC1036 in participants with advanced recurrent or metastatic solid tumors. The trial will be divided into three parts: dose-escalation phase, dose-expansion phase, RP2D-extension phase.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2020-05-11; most recent amendment 2024-10-15.
Status change: Not Yet Recruiting → Recruiting 2020-09-06
Trial Details
NCT Number NCT04387916
Lead Sponsor Beijing Konruns Pharmaceutical Co., Ltd.
Conditions Advanced Solid Tumors
Enrollment 207 participants
Start Date 2020-09-04
Primary Completion 2025-10-31 (estimated)
Study Completion 2025-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-10-17